Loading...
•
Jun 30
Autolus Q2 2025 Earnings Report
Autolus generated $20.9 million in revenue from AUCATZYL in Q2 2025, while expanding commercial access and maintaining a strong cash position.
Key Takeaways
In Q2 2025, Autolus reported $20.9 million in product revenue from AUCATZYL’s U.S. launch and secured market coverage for over 90% of medical lives. Although R&D expenses declined, SG&A costs rose due to commercial scale-up. The company remains well-capitalized with $454.3 million in cash and marketable securities.
Generated $20.9 million in AUCATZYL net revenue for Q2 2025
Activated 46 treatment centers in the U.S. by August 12, 2025
Secured AUCATZYL coverage for over 90% of U.S. medical lives
Ended Q2 with $454.3 million in cash and marketable securities
Autolus
Autolus
Forward Guidance
Autolus expects to advance key trials for lupus nephritis and multiple sclerosis by year-end and plans to present updated clinical data while continuing its global commercial expansion of AUCATZYL.
Positive Outlook
- First patient dosing in LN Phase 2 and MS Phase 1 trials expected by end of 2025
- Additional Phase 1 CARLYSLE data in SLE planned for H2 2025
- Pediatric ALL data (PY01 trial) anticipated in H2 2025
- Strong U.S. commercial momentum for AUCATZYL
- Well-capitalized with $454.3 million in liquidity
Challenges Ahead
- No anticipated EU sales of AUCATZYL through 2026
- Higher SG&A costs driven by commercial scaling
- Pending response to NICE rejection in the UK
- Cash reserves decreased from $588.0 million to $454.3 million
- Delayed R&D tax credit receipt impacted cash flow